Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Nov;12(5):3051-3054.
doi: 10.3892/ol.2016.5108. Epub 2016 Sep 9.

New emerging therapies in the management of chronic lymphocytic leukemia

Xiao-Lin Li  1 , Ci-Xian Zhang  2
Affiliations

New emerging therapies in the management of chronic lymphocytic leukemia

Xiao-Lin Li et al. Oncol Lett. 2016 Nov.

Abstract

Chronic lymphocytic leukemia (CLL) is considered incurable despite advances in management strategies. New drugs targeting cell pathways are currently being developed for the efficient management of CLL. Various strategies involving different targets have been developed, or are currently in the developing stage. A search was conducted in the electronic database PubMed, for pre-clinical as well as clinically controlled trials reporting various strategies against CLL currently under investigation. Novel strategies included use of antibodies, small cell inhibitors, such as spleen tyrosine kinase, LYN, cyclin-dependent kinase, and histone deacetylase inhibitors. The present review examined these new and emerging strategies for the efficient management of CLL. The review involves a discussion of novel strategies being examined worldwide against CLL, including anti-CD20, anti-CD37, anti-CD23, anti-CD40, SYK/LYN inhibitors, BTK inhibitors, p13k inhibitors and recent developments such as the use of cyclin-dependent kinase inhibitors/histone deacetylase inhibitors.

Keywords: antibodies; chronic lymphocytic leukemia; immunotherapy; leukemia; targeted therapy.

PubMed Disclaimer

References

    1. Nabhan C, Chaffee KG, Slager SL, Galanina N, Achenbach SJ, Schwager SM, Kay NE, Shanafelt TD. Analysis of racial variations in disease characteristics, treatment patterns, and outcomes of patients with chronic lymphocytic leukemia. Am J Hematol. 2016 Mar 25; doi: 10.1002/ajh.24374. (Epub ahead of print) - DOI - PubMed
    1. Hallek M, Pflug N. Chronic lymphocytic leukemia. Ann Oncol. 2010;21(Suppl 7):vii154–vii164. - PubMed
    1. Goldin LR, Pfeiffer RM, Li X, Hemminki K. Familial risk of lymphoproliferative tumors in families of patients with chronic lymphocytic leukemia: Results from the Swedish Family-Cancer Database. Blood. 2004;104:1850–1854. doi: 10.1182/blood-2004-01-0341. - DOI - PubMed
    1. Feychting M, Forssén U, Floderus B. Occupational and residential magnetic field exposure and leukemia and central nervous system tumors. Epidemiology. 1997;8:384–389. doi: 10.1097/00001648-199707000-00006. - DOI - PubMed
    1. Ohyashiki JH, Abe K, Ojima T, Wang P, Zhou CF, Suzuki A, Ohyashiki K, Yamamoto K. Quantification of human herpesvirus 6 in healthy volunteers and patients with lymphoproliferative disorders by PCR-ELISA. Leuk Res. 1999;23:625–630. doi: 10.1016/S0145-2126(99)00079-X. - DOI - PubMed